Rezolute, Inc. - (NV) (RZLT) analyst actions
Rating and price-target actions on RZLT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RZLT overview →
1 measured RZLT analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism | Press release | -1.06% | -6.61% |
Keep exploring
More RZLT: earnings → · SEC filings → · RZLT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Tenet Healthcare Corporation (THC) | 363 | +0.22% | 60% |
| Vanda Pharmaceuticals Inc. (VNDA) | 363 | -0.22% | 44% |
| Erytech Pharma S.A. - American Depositary Shares (ERYP) | 360 | 0.00% | 29% |
| AQUINOX PHARMACEUTICALS (AQXP) | 357 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.